A "productive" meeting with the FDA has given the firm confidence in its regulatory filing and commercialization plans for ST-920.

Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease ...

Amicus Therapeutics FOLD reported first-quarter 2025 adjusted earnings of 3 cents per share, which missed the Zacks Consensus Estimate of 8 cents. The company had reported a loss of 2 cents per share ...

Report Ocean’s latest analysis delves into the “Vietnam Fabry Disease Treatment Market” Report from 2024 to 2032, covering an array of market facets such as characteristics, size, growth, segmentation ...

The US Food and Drug Administration (FDA) has awarded breakthrough therapy designation to uniQure's AMT-130 for treating Huntington's disease, a rare neurodegenerative condition. This designation for ...

Background: Neuropathic pain is one of the key features of (classical) Fabry disease (FD). No randomized clinical trials comparing effectiveness of different pain management strategies have been ...

This particular candidate is being developed to treat patients with Fabry Disease. A good update was also provided here a few months ago, whereby the independent data monitoring committee (IDMC ...

He's known for his Saturday morning TV show where he shares weekend recipes, but away from the screen, celebrity chef James Martin has fought a battle with cancer. The 52-year-old has been open ...

A new drug has shown promise in combating Parkinson’s disease while minimizing unwanted side effects. The once-daily pill, tavapadon, was found to relieve symptoms — including stiffness ...

“The concert wasn’t just about music; it was about amplifying the voices of a small but mighty community that refuses to let this disease define them,” said Matt Finlin, the film’s director.

Glycosyrin represents a novel type of ‘iminosugars’, many of which are used as human drugs to treat metabolic disorders such as type-II diabetes and Fabry disease, because they are stable and ...